Maze Therapeutics (NASDAQ:MAZE) Shares Gap Down - Time to Sell?

Key Points

• Maze Therapeutics shares opened lower, falling from a prior close of $29.58 to $28.40 and last trading near $28.06, below the 50-day and 200-day moving averages.
• Analyst sentiment remains broadly positive: the stock has an average “Buy” rating and a $66 consensus price target, despite one recent downgrade to “Sell” and a separate “sell (d-)” rating.
• Insiders sold 108,110 shares worth approximately $3.1 million over the past 90 days, while the company reported quarterly EPS of -$0.76, in line with consensus; analysts expect a full-year loss of $2.72 per share.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $29.58, but opened at $28.40. Maze Therapeutics shares last traded at $28.0550, with a volume of 56,132 shares trading hands.

Wall Street Analyst Weigh In

MAZE has been the topic of several research reports. BTIG Research restated a "buy" rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, August 12th. TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a report on Monday. Wall Street Zen downgraded Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Maze Therapeutics currently has an average rating of "Buy" and a consensus target price of $66.00.

Maze Therapeutics Price Performance

The firm has a 50-day simple moving average of $28.64 and a 200-day simple moving average of $32.04. The firm has a market cap of $1.58 billion, a P/E ratio of -11.25 and a beta of 2.21. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76). As a group, analysts forecast that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Insider Buying and Selling at Maze Therapeutics

In other news, CEO Jason V. Coloma sold 34,501 shares of the firm's stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the sale, the chief executive officer directly owned 23,337 shares in the company, valued at approximately $699,643.26. This trade represents a 59.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the business's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62. Following the transaction, the chief marketing officer owned 16,142 shares of the company's stock, valued at approximately $445,680.62. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 108,110 shares of company stock valued at $3,057,531. 5.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Maze Therapeutics

A number of large investors have recently made changes to their positions in MAZE. Alphabet Inc. acquired a new stake in Maze Therapeutics during the 2nd quarter worth about $41,435,000. TRV GP IV LLC acquired a new position in shares of Maze Therapeutics in the second quarter valued at about $133,502,907,000. Spruce Street Capital LP purchased a new position in shares of Maze Therapeutics in the first quarter worth about $5,970,000. ARCH Venture Management LLC acquired a new stake in shares of Maze Therapeutics during the second quarter worth about $122,983,582,000. Finally, Boothbay Fund Management LLC lifted its holdings in shares of Maze Therapeutics by 16.3% during the fourth quarter. Boothbay Fund Management LLC now owns 409,372 shares of the company's stock worth $16,960,000 after purchasing an additional 57,497 shares during the period.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source